The hazards of intermediate endpoints

被引：8

作者：

Beer, Tomasz M. ^{[1
]}

Ryan, Christopher W. ^{[1
]}

机构：

[1] Oregon Hlth & Sci Univ, Dept Med, Inst Canc, Portland, OR 97239 USA

来源：

CANCER | 2007年 / 110卷 / 09期

关键词：

D O I：

10.1002/cncr.22995

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：1877 / 1879

页数：3

共 9 条

[1]

CARCUDDI MA, 2007, CANCER, V110, P1959

[2] Effect of endothelin-A receptor blockade with atrasentan on tumor progression in men with hormone-refractory prostate cancer: A randomized, phase II, placebo-controlled trial [J].

Carducci, MA ;

Padley, RJ ;

Breul, J ;

Vogelzang, NJ ;

Zonnenberg, BA ;

Daliani, DD ;

Schulman, CC ;

Nabulsi, AA ;

Humerickhouse, RA ;

Weinberg, MA ;

Schmitt, JL ;

Nelson, JB .

JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (04) :679-689

[3]

MOERTEL CG, 1976, CANCER, V38, P388, DOI 10.1002/1097-0142(197607)38:1<388::AID-CNCR2820380156>3.0.CO

[4]

2-A

[5] Clinical significance of a prostate-specific antigen flare phenomenon in patients with hormone-refractory prostate cancer receiving docetaxel [J].

Olbert, Peter Jochen ;

Hegele, Axel ;

Kraeuter, Petra ;

Heidenreich, Axel ;

Hofmann, Rainer ;

Schrader, Andres Jan .

ANTI-CANCER DRUGS, 2006, 17 (08) :993-996

[6] Evaluation of prostate-specific antigen declines for surrogacy in patients treated on SWOG 99-16 [J].

Petrylak, DP ;

Ankerst, DP ;

Jiang, CS ;

Tangen, CM ;

Hussain, MHA ;

Lara, PN ;

Jones, JA ;

Taplin, ME ;

Burch, PA ;

Kohli, M ;

Benson, MC ;

Small, EJ ;

Raghavan, D ;

Crawford, ED .

JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2006, 98 (08) :516-521

[7]

PETRYLAK DP, 2007, P 2007 ASCO PROST CA

[8]

SCHER HI, 2007, P 2007 ASCO PROST CA

[9]

Thompson I M, 2001, Rev Urol, V3 Suppl 3, pS10

← 1 →